180 related articles for article (PubMed ID: 30613868)
1. Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis.
Naylor KE; McCloskey EV; Jacques RM; Peel NFA; Paggiosi MA; Gossiel F; Walsh JS; Eastell R
Osteoporos Int; 2019 Apr; 30(4):917-922. PubMed ID: 30613868
[TBL] [Abstract][Full Text] [Related]
2. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
3. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Naylor KE; Jacques RM; Paggiosi M; Gossiel F; Peel NF; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
[TBL] [Abstract][Full Text] [Related]
4. A dedicated Fracture Liaison Service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates.
van den Berg P; van Haard PMM; van der Veer E; Geusens PP; van den Bergh JP; Schweitzer DH
Osteoporos Int; 2018 Apr; 29(4):813-824. PubMed ID: 29260291
[TBL] [Abstract][Full Text] [Related]
5. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis.
Lorentzon M; Branco J; Brandi ML; Bruyère O; Chapurlat R; Cooper C; Cortet B; Diez-Perez A; Ferrari S; Gasparik A; Herrmann M; Jorgensen NR; Kanis J; Kaufman JM; Laslop A; Locquet M; Matijevic R; McCloskey E; Minisola S; Pikner R; Reginster JY; Rizzoli R; Szulc P; Vlaskovska M; Cavalier E
Adv Ther; 2019 Oct; 36(10):2811-2824. PubMed ID: 31440982
[TBL] [Abstract][Full Text] [Related]
6. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.
Diez-Perez A; Naylor KE; Abrahamsen B; Agnusdei D; Brandi ML; Cooper C; Dennison E; Eriksen EF; Gold DT; Guañabens N; Hadji P; Hiligsmann M; Horne R; Josse R; Kanis JA; Obermayer-Pietsch B; Prieto-Alhambra D; Reginster JY; Rizzoli R; Silverman S; Zillikens MC; Eastell R;
Osteoporos Int; 2017 Mar; 28(3):767-774. PubMed ID: 28093634
[TBL] [Abstract][Full Text] [Related]
7. Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice.
Eekman DA; Bultink IE; Heijboer AC; Dijkmans BA; Lems WF
BMC Musculoskelet Disord; 2011 Jul; 12():167. PubMed ID: 21774839
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
Cosman F; Gilchrist N; McClung M; Foldes J; de Villiers T; Santora A; Leung A; Samanta S; Heyden N; McGinnis JP; Rosenberg E; Denker AE
Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736
[TBL] [Abstract][Full Text] [Related]
9. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
10. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
Uebelhart B; Rizzoli R; Ferrari SL
Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
[TBL] [Abstract][Full Text] [Related]
11. Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia.
Naylor KE; Jacques RM; Peel NF; Gossiel F; Eastell R
Osteoporos Int; 2016 Aug; 27(8):2585-92. PubMed ID: 27026335
[TBL] [Abstract][Full Text] [Related]
12. Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study.
Bønløkke SE; Rand MS; Haddock B; Arup S; Smith CD; Jensen JEB; Schwarz P; Hovind P; Oturai PS; Jensen LT; Møller S; Eiken P; Rubin KH; Hitz MF; Abrahamsen B; Jørgensen NR
Osteoporos Int; 2022 Oct; 33(10):2155-2164. PubMed ID: 35729342
[TBL] [Abstract][Full Text] [Related]
13. The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study.
Ma R; Wu M; Li Y; Wang J; Yang P; Chen Y; Wang W; Song J; Wang K
J Orthop Surg Res; 2021 Mar; 16(1):195. PubMed ID: 33731168
[TBL] [Abstract][Full Text] [Related]
14. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
15. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
16. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
[TBL] [Abstract][Full Text] [Related]
17. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Lai PS; Chua SS; Chew YY; Chan SP
J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
[TBL] [Abstract][Full Text] [Related]
18. The predictive value of bone turnover markers during discontinuation of alendronate: the PROSA study.
Sølling AS; Harsløf T; Bruun NH; Langdahl B
Osteoporos Int; 2021 Aug; 32(8):1557-1566. PubMed ID: 33517477
[TBL] [Abstract][Full Text] [Related]
19. Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting.
Roberts J; Castro C; Moore AE; Fogelman I; Hampson G
Clin Endocrinol (Oxf); 2016 Apr; 84(4):509-15. PubMed ID: 26715263
[TBL] [Abstract][Full Text] [Related]
20. The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis.
Fontalis A; Eastell R
Bone; 2020 Jul; 136():115336. PubMed ID: 32234415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]